Table 1.
Patient Characteristics Before and After Propensity Score Matching
| Before Propensity Score Matching | After Propensity Score Matching | |||||
|---|---|---|---|---|---|---|
| Sorafenib | Lenvatinib | P value | Sorafenib | Lenvatinib | P value | |
| % | % | % | % | |||
| N = 289 Patients | N = 144 Patients | N = 144 Patients | N = 144 Patients | |||
| Gender | ||||||
| Male | 85.5 | 77.1 | 82.6 | 77.1 | 0.24 | |
| Female | 14.5 | 22.9 | 0.48 | 17.4 | 22.9 | |
| Age | ||||||
| <70 | 54.0 | 52.8 | 52.7 | 52.8 | 1.00 | |
| >70 | 46.0 | 47.2 | 0.83 | 68 | 47.2 | |
| Etiology | ||||||
| HCV | 48.8 | 46.5 | 48.6 | 46.5 | 0.34 | |
| HBV | 20.8 | 15.2 | 21.5 | 15.2 | ||
| NASH | 11.1 | 13.9 | 12.5 | 13.9 | ||
| Others | 19.3 | 24.4 | 0.33 | 17.4 | 24.4 | |
| TACE before | ||||||
| Yes | 44.3 | 41.0 | 41.0 | 41.0 | 1.00 | |
| No | 55.7 | 59.0 | 0.53 | 59.0 | 59.0 | |
| Child-Pugh | ||||||
| A | 88.6 | 94.9 | 93.0 | 94.9 | 0.61 | |
| B | 11.4 | 5.1 | 0.03 | 7.0 | 5.1 | |
| BCLC | ||||||
| C | 81.3 | 75.0 | 75.0 | 75.0 | 1.00 | |
| B | 18.7 | 25.0 | 0.12 | 25.0 | 25.0 | |
| ECOG | ||||||
| 0 | 58.5 | 78.9 | 78.9 | 78.9 | 1.00 | |
| >0 | 41.5 | 21.1 | 0.000025 | 21.1 | 21.1 | |
| AFP | ||||||
| <400 | 69.2 | 64.6 | 69.3 | 64.6 | 0.43 | |
| >400 | 30.8 | 35.4 | 0.07 | 30.7 | 35.4 | |
| NLR | ||||||
| <3 | 60.4 | 65.1 | 65.4 | 65.1 | 1.00 | |
| >3 | 39.6 | 34.9 | 0.38 | 34.6 | 34.9 | |
| Bilirubin | ||||||
| <NV | 80.1 | 64.0 | 66.9 | 64.0 | 0.70 | |
| >NV | 19.9 | 36.0 | 0.006 | 33.1 | 36.0 | |
| Albumin | ||||||
| <35 | 24.2 | 13.5 | 21.3 | 13.5 | 0.13 | |
| >35 | 75.8 | 86.5 | 0.53 | 78.7 | 86.5 | |